Key Takeaways Danaher's Life Sciences core revenues fell 4% in Q1 and 2.5% in Q2 year over year.Weak demand in academic, government and biotech markets hurt key product lines.New products and biotech breakthroughs highlight growth potential despite risks.Danaher Corporation (DHR) is facing continued softness in its Life Sciences segment. In first-quarter 2025, core revenues from the segment declined 4% on a year-over-year basis. In the second quarter, the same decreased 2.5% year over year.The drop was prim ...